1. | jordanjames7 | |
2. | wolvergeek | |
3. | danielwilliamsms | |
4. | dlrothwell | |
5. | 7946manley049 |
1. | jordanjames7 | |
2. | wolvergeek | |
3. | danielwilliamsms | |
4. | dlrothwell | |
5. | 7946manley049 |
1. | jordanjames7 01/22/2018 Product expansion |
2. | 7946manley049 01/26/2018 $25 Million Payment |
3. | danielwilliamsms 06/04/2018 Announces results from Phase 3 CheckMate -227 |
4. | 7946manley049 01/29/2018 BMY Feb 62 calls are seeing interest with 6970 contracts trading |
5. | jordanjames7 04/16/2018 Announces initial results from pivotal Phase 3 study (CheckMate -227) evaluating Opdivo 3 mg/kg plus low-dose… |
6. | jordanjames7 01/26/2018 Crickets... Nobody? |
7. | danielwilliamsms 05/01/2018 Bristol-Myers abandons Phase 3 IDO |
8. | dlrothwell 02/05/2018 $BMY. news. - Announces that the ongoing Phase 3 CheckMate -227 study met its co-primary endpoint of progression-free survi… |
9. | wolvergeek 02/15/2018 Breakthrough Anti-cancer Drug Candidates Targeting Potential Best-in-class Therapies for 2018 |
10. | wolvergeek 02/05/2018 Yes, by all means go down so I can buy more |